SCHEMBL724200

SCHEMBL724200

COCCOc1cc(-c2ccnc3cc(-c4cc(OC)c(OC)c(OC)c4)oc23)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4C Q08493 3/20 0.42
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
CYP1A1 P04798 3/20 0.36
CYP1B1 Q16678 3/20 0.36
CYP1A2 P05177 2/20 0.36
SYK P43405 2/20 0.36
BRD4 O60885 4/20 0.36
PTGES O14684 1/20 0.36
ALOX5 P09917 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
CYP3A4 P08684 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723624 0.89 PDE4C (0.47) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL723093 0.84 PDE4C (0.55) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL15210385 0.81 PDE4C (0.46) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL722839 0.80 PDE4C (0.51) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL16638610 0.79 PDE4C (0.47) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL722596 0.79 PDE4C (0.50) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL725087 0.78 FYN (0.53) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL16638609 0.78 PDE4C (0.50) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL722239 0.78 TERT (0.47) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL722937 0.78 FYN (0.48) PDE4CJAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PDE4C 2858/4885JAK2 14/4885JAK1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.